Trials / Completed
CompletedNCT00077844
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
An International Phase 2-3, Stratified, Randomized, Open-label, Parallel-group Clinical Trial to Evaluate the Safety and Efficacy of a Single Intravenous Bolus of Enoxaparin Versus Intravenous Unfractionated Heparin in Patients Undergoing Non-emergent Percutaneous Coronary Intervention
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 3,532 (estimated)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of intravenous enoxaparin versus intravenous unfractionated heparin (UFH) in patients undergoing non-emergent PCI, as assessed by measuring the incidence of non-coronary artery bypass graft (CABG) major and minor bleeding.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enoxaparin sodium |
Timeline
- Start date
- 2004-01-01
- Primary completion
- 2005-09-01
- Completion
- 2005-09-01
- First posted
- 2004-02-18
- Last updated
- 2011-01-11
Source: ClinicalTrials.gov record NCT00077844. Inclusion in this directory is not an endorsement.